| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 115 | 2024 | 15912 | 3.820 |
Why?
|
| High-Throughput Nucleotide Sequencing | 55 | 2024 | 2359 | 3.770 |
Why?
|
| Leukemia, Myeloid, Acute | 67 | 2024 | 7265 | 3.140 |
Why?
|
| Myeloproliferative Disorders | 20 | 2024 | 882 | 2.890 |
Why?
|
| DNA Mutational Analysis | 32 | 2022 | 2357 | 2.840 |
Why?
|
| Isocitrate Dehydrogenase | 12 | 2022 | 522 | 2.170 |
Why?
|
| Myelodysplastic Syndromes | 26 | 2024 | 3156 | 1.770 |
Why?
|
| Hematologic Neoplasms | 17 | 2023 | 1956 | 1.720 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 15 | 2023 | 2486 | 1.420 |
Why?
|
| Primary Myelofibrosis | 12 | 2022 | 914 | 1.390 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 16 | 2024 | 838 | 1.330 |
Why?
|
| Neoplasm Proteins | 13 | 2022 | 3345 | 1.250 |
Why?
|
| Calreticulin | 4 | 2016 | 86 | 1.240 |
Why?
|
| Biomarkers, Tumor | 30 | 2024 | 10708 | 1.160 |
Why?
|
| Tumor Suppressor Protein p53 | 20 | 2024 | 3658 | 1.150 |
Why?
|
| Neoplasms | 31 | 2024 | 15927 | 0.980 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2018 | 232 | 0.960 |
Why?
|
| Polymerase Chain Reaction | 10 | 2019 | 3476 | 0.950 |
Why?
|
| Sequence Analysis, DNA | 15 | 2020 | 2573 | 0.920 |
Why?
|
| Humans | 223 | 2024 | 270740 | 0.910 |
Why?
|
| Lymphoma, B-Cell | 2 | 2023 | 929 | 0.910 |
Why?
|
| Proto-Oncogene Proteins B-raf | 13 | 2018 | 1336 | 0.900 |
Why?
|
| Aged | 116 | 2024 | 73333 | 0.900 |
Why?
|
| Receptor, Notch1 | 2 | 2022 | 217 | 0.890 |
Why?
|
| Fusion Proteins, bcr-abl | 8 | 2023 | 1144 | 0.880 |
Why?
|
| Middle Aged | 124 | 2024 | 90352 | 0.860 |
Why?
|
| Prognosis | 49 | 2023 | 22505 | 0.850 |
Why?
|
| Leukemia, Myeloid | 3 | 2017 | 993 | 0.830 |
Why?
|
| Aged, 80 and over | 74 | 2024 | 30998 | 0.830 |
Why?
|
| Lymphoma | 5 | 2023 | 1519 | 0.820 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 8 | 2023 | 214 | 0.810 |
Why?
|
| Bone Marrow | 20 | 2024 | 2441 | 0.800 |
Why?
|
| Adult | 111 | 2024 | 82040 | 0.790 |
Why?
|
| Male | 131 | 2024 | 128315 | 0.760 |
Why?
|
| Janus Kinase 2 | 9 | 2022 | 754 | 0.720 |
Why?
|
| Clonal Evolution | 5 | 2020 | 250 | 0.710 |
Why?
|
| Germ-Line Mutation | 8 | 2023 | 1101 | 0.700 |
Why?
|
| Immunohistochemistry | 15 | 2024 | 7655 | 0.700 |
Why?
|
| Female | 132 | 2024 | 148940 | 0.690 |
Why?
|
| Nuclear Proteins | 13 | 2023 | 3438 | 0.680 |
Why?
|
| Genomics | 12 | 2023 | 2835 | 0.640 |
Why?
|
| Leukemia, Hairy Cell | 3 | 2018 | 129 | 0.630 |
Why?
|
| Nucleic Acid Denaturation | 2 | 2016 | 50 | 0.630 |
Why?
|
| Leukemia | 4 | 2023 | 1719 | 0.630 |
Why?
|
| Repressor Proteins | 6 | 2021 | 1718 | 0.620 |
Why?
|
| Megakaryocytes | 2 | 2016 | 129 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 16689 | 0.600 |
Why?
|
| Immunophenotyping | 13 | 2023 | 1726 | 0.580 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2023 | 4961 | 0.570 |
Why?
|
| Genotype | 6 | 2017 | 4252 | 0.570 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2015 | 128 | 0.570 |
Why?
|
| Translocation, Genetic | 8 | 2024 | 1286 | 0.570 |
Why?
|
| Young Adult | 48 | 2024 | 22251 | 0.570 |
Why?
|
| Neoplasm, Residual | 11 | 2023 | 1754 | 0.570 |
Why?
|
| Leukemia, Promyelocytic, Acute | 4 | 2024 | 441 | 0.560 |
Why?
|
| Stem Cell Transplantation | 6 | 2020 | 1418 | 0.550 |
Why?
|
| Lymphoma, Mantle-Cell | 5 | 2022 | 750 | 0.550 |
Why?
|
| Leukemia, B-Cell | 1 | 2017 | 114 | 0.540 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 15 | 2023 | 7044 | 0.540 |
Why?
|
| Chromosome Aberrations | 7 | 2023 | 2035 | 0.540 |
Why?
|
| Transition Temperature | 1 | 2016 | 7 | 0.530 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 4 | 2022 | 121 | 0.520 |
Why?
|
| Genetic Testing | 4 | 2019 | 1696 | 0.510 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2017 | 172 | 0.500 |
Why?
|
| Antibodies | 1 | 2018 | 809 | 0.490 |
Why?
|
| Recurrence | 14 | 2024 | 4878 | 0.490 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2021 | 389 | 0.480 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 276 | 0.460 |
Why?
|
| Karyotype | 8 | 2019 | 237 | 0.460 |
Why?
|
| Exons | 7 | 2018 | 1383 | 0.460 |
Why?
|
| Real-Time Polymerase Chain Reaction | 6 | 2020 | 1199 | 0.450 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2023 | 2617 | 0.450 |
Why?
|
| Patients | 1 | 2016 | 246 | 0.450 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 3 | 2023 | 120 | 0.450 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2024 | 5776 | 0.450 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2023 | 2635 | 0.440 |
Why?
|
| MAP Kinase Kinase 1 | 4 | 2018 | 161 | 0.430 |
Why?
|
| DNA Copy Number Variations | 6 | 2017 | 1568 | 0.420 |
Why?
|
| In Situ Hybridization, Fluorescence | 14 | 2023 | 2313 | 0.420 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 691 | 0.420 |
Why?
|
| Gene Fusion | 4 | 2023 | 214 | 0.420 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2012 | 56 | 0.410 |
Why?
|
| Gene Frequency | 4 | 2020 | 1246 | 0.410 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2016 | 285 | 0.410 |
Why?
|
| Antineoplastic Agents | 14 | 2021 | 14617 | 0.410 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 8 | 2022 | 1402 | 0.400 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 3 | 2023 | 531 | 0.400 |
Why?
|
| Family | 1 | 2016 | 783 | 0.390 |
Why?
|
| Reproducibility of Results | 15 | 2021 | 6177 | 0.390 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 4 | 2015 | 314 | 0.390 |
Why?
|
| Workflow | 6 | 2019 | 279 | 0.390 |
Why?
|
| DEAD-box RNA Helicases | 4 | 2023 | 256 | 0.390 |
Why?
|
| Philadelphia Chromosome | 3 | 2022 | 852 | 0.390 |
Why?
|
| Neoplasms, Second Primary | 5 | 2019 | 1388 | 0.380 |
Why?
|
| GTP Phosphohydrolases | 4 | 2019 | 339 | 0.380 |
Why?
|
| Adolescent | 33 | 2024 | 32767 | 0.380 |
Why?
|
| Thiazoles | 1 | 2015 | 723 | 0.370 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2024 | 5408 | 0.360 |
Why?
|
| Pyrimidines | 5 | 2020 | 3669 | 0.360 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 3 | 2023 | 460 | 0.360 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2010 | 67 | 0.350 |
Why?
|
| Remission Induction | 9 | 2023 | 3656 | 0.350 |
Why?
|
| Azacitidine | 7 | 2024 | 1218 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2024 | 484 | 0.340 |
Why?
|
| Leukemia, Mast-Cell | 2 | 2020 | 15 | 0.320 |
Why?
|
| DNA, Neoplasm | 6 | 2018 | 1958 | 0.320 |
Why?
|
| Alleles | 6 | 2019 | 2600 | 0.320 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2024 | 1739 | 0.320 |
Why?
|
| Survival Rate | 15 | 2022 | 12541 | 0.320 |
Why?
|
| Core Binding Factors | 2 | 2020 | 112 | 0.310 |
Why?
|
| Pyrazoles | 3 | 2018 | 1546 | 0.310 |
Why?
|
| Genes, p53 | 4 | 2017 | 1140 | 0.310 |
Why?
|
| Disease-Free Survival | 14 | 2023 | 10265 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 5 | 2021 | 797 | 0.300 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2023 | 334 | 0.290 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2020 | 156 | 0.290 |
Why?
|
| Serine-Arginine Splicing Factors | 4 | 2023 | 84 | 0.290 |
Why?
|
| Histiocytosis, Sinus | 2 | 2018 | 86 | 0.280 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2020 | 1067 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 2017 | 668 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 9042 | 0.280 |
Why?
|
| RNA, Neoplasm | 2 | 2021 | 805 | 0.270 |
Why?
|
| Skin Neoplasms | 8 | 2018 | 4895 | 0.270 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2020 | 232 | 0.270 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2017 | 185 | 0.260 |
Why?
|
| Thrombocythemia, Essential | 3 | 2017 | 179 | 0.260 |
Why?
|
| DNA | 2 | 2014 | 3050 | 0.260 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 2903 | 0.260 |
Why?
|
| Eosinophilia | 2 | 2020 | 182 | 0.260 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2016 | 123 | 0.250 |
Why?
|
| Skin Diseases | 2 | 2020 | 366 | 0.250 |
Why?
|
| Mastocytosis, Systemic | 2 | 2024 | 119 | 0.250 |
Why?
|
| Lymphadenopathy | 3 | 2022 | 94 | 0.250 |
Why?
|
| Retrospective Studies | 30 | 2024 | 39890 | 0.250 |
Why?
|
| RNA Splicing Factors | 2 | 2023 | 151 | 0.250 |
Why?
|
| DNA-Binding Proteins | 7 | 2021 | 5002 | 0.240 |
Why?
|
| Membrane Proteins | 5 | 2019 | 2928 | 0.240 |
Why?
|
| Polycythemia Vera | 3 | 2017 | 268 | 0.240 |
Why?
|
| Acute Disease | 4 | 2022 | 2493 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2018 | 2453 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2020 | 4644 | 0.240 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 1013 | 0.230 |
Why?
|
| Medical Records | 2 | 2015 | 442 | 0.230 |
Why?
|
| Isochromosomes | 2 | 2022 | 55 | 0.230 |
Why?
|
| Core Binding Factor beta Subunit | 2 | 2021 | 50 | 0.230 |
Why?
|
| Tretinoin | 2 | 2024 | 617 | 0.230 |
Why?
|
| Myosin Heavy Chains | 2 | 2021 | 122 | 0.230 |
Why?
|
| Dasatinib | 2 | 2020 | 881 | 0.230 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 5149 | 0.220 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 513 | 0.220 |
Why?
|
| ras Proteins | 4 | 2021 | 804 | 0.220 |
Why?
|
| Biomarkers | 6 | 2022 | 5051 | 0.220 |
Why?
|
| Pyrazines | 2 | 2024 | 510 | 0.220 |
Why?
|
| Dioxygenases | 4 | 2021 | 173 | 0.220 |
Why?
|
| World Health Organization | 3 | 2022 | 327 | 0.210 |
Why?
|
| WT1 Proteins | 2 | 2022 | 107 | 0.210 |
Why?
|
| Mutation, Missense | 3 | 2017 | 1192 | 0.210 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2017 | 284 | 0.210 |
Why?
|
| Hodgkin Disease | 2 | 2022 | 1485 | 0.210 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 2 | 2020 | 67 | 0.210 |
Why?
|
| Treatment Outcome | 24 | 2024 | 33737 | 0.210 |
Why?
|
| Mast Cells | 1 | 2024 | 229 | 0.210 |
Why?
|
| Survival Analysis | 10 | 2021 | 9292 | 0.210 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 283 | 0.210 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 304 | 0.200 |
Why?
|
| Aniline Compounds | 1 | 2024 | 206 | 0.200 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 4960 | 0.200 |
Why?
|
| Cytodiagnosis | 2 | 2020 | 201 | 0.200 |
Why?
|
| Histiocytosis | 1 | 2022 | 55 | 0.200 |
Why?
|
| Sensitivity and Specificity | 9 | 2017 | 5162 | 0.200 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2022 | 75 | 0.190 |
Why?
|
| Sequence Analysis, RNA | 2 | 2023 | 676 | 0.190 |
Why?
|
| Blood Platelet Disorders | 1 | 2021 | 35 | 0.190 |
Why?
|
| Biopsy | 9 | 2021 | 3484 | 0.190 |
Why?
|
| Granuloma | 1 | 2022 | 153 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2024 | 10400 | 0.190 |
Why?
|
| Sulfonamides | 4 | 2024 | 1933 | 0.190 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2014 | 244 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2023 | 3597 | 0.190 |
Why?
|
| Gene Rearrangement | 3 | 2023 | 813 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 350 | 0.190 |
Why?
|
| MicroRNAs | 1 | 2014 | 2887 | 0.190 |
Why?
|
| Bone Marrow Cells | 2 | 2018 | 968 | 0.180 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2022 | 180 | 0.180 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2021 | 48 | 0.180 |
Why?
|
| Melanoma | 6 | 2015 | 5595 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6256 | 0.180 |
Why?
|
| Idarubicin | 3 | 2024 | 459 | 0.180 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2020 | 35 | 0.180 |
Why?
|
| Arsenicals | 1 | 2021 | 205 | 0.180 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2022 | 264 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 1542 | 0.180 |
Why?
|
| Cytological Techniques | 1 | 2020 | 69 | 0.180 |
Why?
|
| Transplantation, Homologous | 7 | 2021 | 3046 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 65 | 0.180 |
Why?
|
| Cohort Studies | 11 | 2022 | 9470 | 0.180 |
Why?
|
| Lymphoma, T-Cell | 2 | 2016 | 366 | 0.180 |
Why?
|
| Algorithms | 1 | 2011 | 3891 | 0.170 |
Why?
|
| Pyridazines | 1 | 2023 | 324 | 0.170 |
Why?
|
| DNA Methylation | 3 | 2021 | 2765 | 0.170 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2020 | 95 | 0.170 |
Why?
|
| Tandem Repeat Sequences | 3 | 2020 | 203 | 0.170 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 204 | 0.170 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 15218 | 0.170 |
Why?
|
| Lymphopenia | 1 | 2022 | 211 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2016 | 275 | 0.170 |
Why?
|
| Base Sequence | 5 | 2014 | 5437 | 0.170 |
Why?
|
| Dendritic Cells | 2 | 2017 | 1110 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 2471 | 0.160 |
Why?
|
| Anemia, Sideroblastic | 1 | 2019 | 57 | 0.160 |
Why?
|
| Cytarabine | 4 | 2022 | 2014 | 0.160 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2019 | 53 | 0.160 |
Why?
|
| Sequence Deletion | 4 | 2014 | 909 | 0.160 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 347 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 2399 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2016 | 586 | 0.160 |
Why?
|
| Abnormal Karyotype | 1 | 2018 | 101 | 0.150 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2021 | 460 | 0.150 |
Why?
|
| Cyclin D1 | 1 | 2020 | 589 | 0.150 |
Why?
|
| Breast Implantation | 1 | 2021 | 222 | 0.150 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2018 | 17 | 0.150 |
Why?
|
| Time Factors | 8 | 2019 | 13006 | 0.150 |
Why?
|
| Mediastinal Neoplasms | 1 | 2022 | 427 | 0.150 |
Why?
|
| Karyotyping | 5 | 2021 | 1063 | 0.150 |
Why?
|
| Phenotype | 6 | 2020 | 6509 | 0.150 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2020 | 689 | 0.150 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2018 | 50 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 560 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2018 | 375 | 0.150 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 164 | 0.150 |
Why?
|
| Antibody Specificity | 1 | 2018 | 336 | 0.150 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2019 | 166 | 0.150 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 338 | 0.150 |
Why?
|
| Datasets as Topic | 1 | 2018 | 178 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 761 | 0.140 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 198 | 0.140 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2017 | 15 | 0.140 |
Why?
|
| Gene Amplification | 2 | 2017 | 766 | 0.140 |
Why?
|
| Carrier Proteins | 2 | 2016 | 2098 | 0.140 |
Why?
|
| Leukemia, Lymphoid | 1 | 2017 | 289 | 0.140 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 657 | 0.140 |
Why?
|
| Bone Marrow Diseases | 1 | 2018 | 186 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 481 | 0.140 |
Why?
|
| Pancytopenia | 1 | 2017 | 119 | 0.140 |
Why?
|
| Oncogene Fusion | 1 | 2016 | 62 | 0.140 |
Why?
|
| Myeloid Cells | 1 | 2018 | 273 | 0.140 |
Why?
|
| Breast Implants | 1 | 2021 | 375 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 885 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 870 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 425 | 0.140 |
Why?
|
| Pathology Department, Hospital | 1 | 2016 | 15 | 0.140 |
Why?
|
| Genes, erbB-1 | 2 | 2016 | 104 | 0.130 |
Why?
|
| Validation Studies as Topic | 1 | 2016 | 42 | 0.130 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 331 | 0.130 |
Why?
|
| Vincristine | 4 | 2022 | 1583 | 0.130 |
Why?
|
| Anemia, Aplastic | 1 | 2018 | 232 | 0.130 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 1049 | 0.130 |
Why?
|
| Immunologic Factors | 2 | 2017 | 672 | 0.130 |
Why?
|
| Pedigree | 2 | 2019 | 2042 | 0.130 |
Why?
|
| Splenic Neoplasms | 1 | 2016 | 124 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2018 | 337 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 232 | 0.130 |
Why?
|
| Mycosis Fungoides | 2 | 2018 | 341 | 0.130 |
Why?
|
| Karyopherins | 1 | 2016 | 134 | 0.130 |
Why?
|
| Plasma Cells | 2 | 2015 | 197 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2019 | 2166 | 0.120 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 381 | 0.120 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 79 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 359 | 0.120 |
Why?
|
| Skin | 3 | 2017 | 1271 | 0.120 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 1099 | 0.120 |
Why?
|
| Sweet Syndrome | 1 | 2014 | 35 | 0.120 |
Why?
|
| Castleman Disease | 1 | 2015 | 71 | 0.120 |
Why?
|
| Diagnosis, Differential | 6 | 2024 | 4831 | 0.120 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2014 | 67 | 0.120 |
Why?
|
| Semiconductors | 1 | 2014 | 20 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 525 | 0.120 |
Why?
|
| Stem Cells | 1 | 2021 | 1216 | 0.120 |
Why?
|
| Thymoma | 1 | 2018 | 252 | 0.120 |
Why?
|
| Standard of Care | 1 | 2016 | 277 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 680 | 0.120 |
Why?
|
| Nitriles | 2 | 2018 | 939 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2022 | 2431 | 0.110 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 231 | 0.110 |
Why?
|
| Nevus, Blue | 1 | 2014 | 40 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2016 | 307 | 0.110 |
Why?
|
| Carcinoma | 2 | 2023 | 2610 | 0.110 |
Why?
|
| Precision Medicine | 3 | 2020 | 1207 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 130 | 0.110 |
Why?
|
| Smad4 Protein | 1 | 2015 | 201 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2014 | 98 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 1942 | 0.110 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 206 | 0.110 |
Why?
|
| Genetic Counseling | 1 | 2016 | 417 | 0.110 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 367 | 0.110 |
Why?
|
| CD4 Antigens | 1 | 2013 | 170 | 0.110 |
Why?
|
| Chromosome Deletion | 2 | 2015 | 1049 | 0.110 |
Why?
|
| CD8 Antigens | 1 | 2013 | 174 | 0.110 |
Why?
|
| Transcription Factors | 5 | 2022 | 5438 | 0.110 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2013 | 33 | 0.110 |
Why?
|
| Disease Progression | 7 | 2020 | 6867 | 0.110 |
Why?
|
| Lymph Nodes | 3 | 2020 | 3077 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 654 | 0.110 |
Why?
|
| Spleen | 1 | 2015 | 726 | 0.110 |
Why?
|
| Child | 11 | 2024 | 30559 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 1580 | 0.100 |
Why?
|
| Risk Factors | 9 | 2021 | 17888 | 0.100 |
Why?
|
| Splicing Factor U2AF | 2 | 2023 | 47 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 1838 | 0.100 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 416 | 0.100 |
Why?
|
| Transcriptome | 1 | 2021 | 1963 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 234 | 0.100 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 314 | 0.100 |
Why?
|
| Genes, ras | 1 | 2015 | 679 | 0.100 |
Why?
|
| Chromosome Disorders | 1 | 2015 | 423 | 0.100 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2012 | 43 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2017 | 959 | 0.100 |
Why?
|
| Cytogenetic Analysis | 3 | 2020 | 574 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 376 | 0.100 |
Why?
|
| Niacinamide | 1 | 2014 | 428 | 0.100 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2012 | 70 | 0.100 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 5101 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 965 | 0.100 |
Why?
|
| Poly A | 1 | 2012 | 96 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 617 | 0.100 |
Why?
|
| Oncogenes | 2 | 2013 | 699 | 0.100 |
Why?
|
| Cell Line, Tumor | 6 | 2018 | 14849 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 1051 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 1823 | 0.090 |
Why?
|
| Thalidomide | 1 | 2014 | 597 | 0.090 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 192 | 0.090 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 2328 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 339 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 1367 | 0.090 |
Why?
|
| Models, Biological | 1 | 2019 | 3194 | 0.090 |
Why?
|
| Salvage Therapy | 4 | 2024 | 2123 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2011 | 188 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 600 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 190 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 2027 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 2374 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 12033 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2016 | 931 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2015 | 2311 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 678 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 1340 | 0.090 |
Why?
|
| Microsatellite Instability | 1 | 2012 | 408 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 602 | 0.090 |
Why?
|
| Thyroid Neoplasms | 2 | 2018 | 1894 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 2 | 2017 | 2651 | 0.080 |
Why?
|
| Time | 2 | 2020 | 183 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2024 | 329 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 2011 | 367 | 0.080 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2012 | 331 | 0.080 |
Why?
|
| Age Factors | 4 | 2020 | 5457 | 0.080 |
Why?
|
| Methotrexate | 2 | 2022 | 1025 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 3530 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 1347 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 3707 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 1710 | 0.080 |
Why?
|
| Doxorubicin | 3 | 2022 | 3145 | 0.080 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2008 | 17 | 0.080 |
Why?
|
| Retinoic Acid Receptor alpha | 2 | 2020 | 94 | 0.080 |
Why?
|
| Rituximab | 3 | 2022 | 1594 | 0.080 |
Why?
|
| Gene Dosage | 3 | 2017 | 823 | 0.070 |
Why?
|
| Macrophages, Peritoneal | 1 | 2008 | 71 | 0.070 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 3245 | 0.070 |
Why?
|
| Therapeutic Irrigation | 1 | 2008 | 92 | 0.070 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 66 | 0.070 |
Why?
|
| Keratin-6 | 1 | 2007 | 40 | 0.070 |
Why?
|
| Keratin-5 | 1 | 2007 | 57 | 0.070 |
Why?
|
| DNA Primers | 1 | 2010 | 1496 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2021 | 3045 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2018 | 7238 | 0.070 |
Why?
|
| Splenectomy | 2 | 2020 | 168 | 0.070 |
Why?
|
| Adenine | 2 | 2022 | 674 | 0.070 |
Why?
|
| Child, Preschool | 6 | 2020 | 17061 | 0.070 |
Why?
|
| Paraffin Embedding | 2 | 2018 | 223 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 557 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 2008 | 328 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2019 | 6764 | 0.070 |
Why?
|
| Tissue Fixation | 2 | 2017 | 137 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 6685 | 0.070 |
Why?
|
| Splenomegaly | 2 | 2017 | 173 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2016 | 6390 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5574 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1456 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 1655 | 0.060 |
Why?
|
| Mutation Rate | 2 | 2018 | 220 | 0.060 |
Why?
|
| Texas | 1 | 2016 | 6449 | 0.060 |
Why?
|
| Imidazoles | 2 | 2023 | 1065 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2020 | 770 | 0.060 |
Why?
|
| Piperidines | 2 | 2022 | 1100 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3949 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2015 | 149 | 0.060 |
Why?
|
| GATA2 Transcription Factor | 1 | 2023 | 67 | 0.050 |
Why?
|
| Mutagenesis, Insertional | 2 | 2015 | 219 | 0.050 |
Why?
|
| Dexamethasone | 2 | 2019 | 1516 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 2007 | 414 | 0.050 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 14012 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2022 | 80 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 1385 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 287 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 1584 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 16215 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2021 | 2250 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 329 | 0.050 |
Why?
|
| Chimerism | 1 | 2021 | 65 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2021 | 174 | 0.050 |
Why?
|
| Surface Properties | 1 | 2021 | 189 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 115 | 0.050 |
Why?
|
| Animals | 8 | 2021 | 61956 | 0.050 |
Why?
|
| Oxides | 1 | 2021 | 212 | 0.050 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2020 | 56 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 999 | 0.040 |
Why?
|
| Benzylamines | 1 | 2020 | 98 | 0.040 |
Why?
|
| Lymphocytosis | 1 | 2020 | 57 | 0.040 |
Why?
|
| Chromosome Inversion | 1 | 2021 | 197 | 0.040 |
Why?
|
| Triazines | 1 | 2021 | 121 | 0.040 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2020 | 37 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 13414 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 9039 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2020 | 117 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 153 | 0.040 |
Why?
|
| Melphalan | 1 | 2023 | 879 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2021 | 257 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4958 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 273 | 0.040 |
Why?
|
| Mice | 6 | 2020 | 35600 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 469 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2020 | 186 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 223 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 533 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 64 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4821 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2017 | 1857 | 0.040 |
Why?
|
| Glycine | 1 | 2021 | 322 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 653 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2023 | 764 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 1063 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2008 | 1302 | 0.040 |
Why?
|
| Cyclohexanes | 1 | 2018 | 41 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 896 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 738 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2023 | 2067 | 0.040 |
Why?
|
| Prednisolone | 1 | 2018 | 132 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 366 | 0.040 |
Why?
|
| Chromothripsis | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cytotoxins | 1 | 2017 | 65 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2020 | 450 | 0.040 |
Why?
|
| Clinical Laboratory Services | 1 | 2017 | 39 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2023 | 1033 | 0.040 |
Why?
|
| Antilymphocyte Serum | 1 | 2018 | 237 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2022 | 1138 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2019 | 470 | 0.030 |
Why?
|
| Molecular Probes | 1 | 2017 | 71 | 0.030 |
Why?
|
| Safety | 1 | 2018 | 460 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2018 | 292 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 867 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2018 | 175 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 709 | 0.030 |
Why?
|
| Therapeutics | 1 | 2016 | 30 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2017 | 313 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 1017 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 2016 | 71 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 1163 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2020 | 1691 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 150 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 139 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 591 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 396 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2015 | 28 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 512 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1090 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 185 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2019 | 505 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2016 | 227 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 461 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2015 | 170 | 0.030 |
Why?
|
| Codon | 1 | 2015 | 261 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2016 | 234 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 240 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 690 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2017 | 282 | 0.030 |
Why?
|
| Kinetics | 1 | 2018 | 2220 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2015 | 197 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 670 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2015 | 107 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 291 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 623 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 678 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 168 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2014 | 36 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 1697 | 0.030 |
Why?
|
| Pentostatin | 1 | 2014 | 121 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2014 | 152 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 737 | 0.030 |
Why?
|
| Drug Approval | 1 | 2015 | 174 | 0.030 |
Why?
|
| Pyridines | 1 | 2021 | 1313 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2184 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 323 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2211 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2014 | 123 | 0.030 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 354 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1350 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 2057 | 0.030 |
Why?
|
| Benzamides | 1 | 2018 | 1879 | 0.030 |
Why?
|
| Vidarabine | 1 | 2018 | 1384 | 0.030 |
Why?
|
| Cladribine | 1 | 2014 | 253 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 1075 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 529 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 316 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1824 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 850 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1655 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 5338 | 0.030 |
Why?
|
| Microdissection | 1 | 2012 | 85 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 2828 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 596 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 566 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2021 | 12103 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 3028 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1379 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 1322 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2375 | 0.020 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2011 | 85 | 0.020 |
Why?
|
| Infant | 2 | 2017 | 13999 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2011 | 172 | 0.020 |
Why?
|
| Nose Neoplasms | 1 | 2013 | 242 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 1472 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 788 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2018 | 4329 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 1093 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 1291 | 0.020 |
Why?
|
| Software | 1 | 2017 | 1355 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 1903 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2015 | 1474 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1034 | 0.020 |
Why?
|
| Pregnancy | 1 | 2023 | 8130 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 1604 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 2090 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2014 | 677 | 0.020 |
Why?
|
| Piperazines | 1 | 2018 | 2145 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 7914 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 2197 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 6224 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2013 | 1418 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 2170 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 2351 | 0.020 |
Why?
|
| United States | 2 | 2016 | 15861 | 0.020 |
Why?
|
| Povidone-Iodine | 1 | 2008 | 16 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 2033 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 3557 | 0.020 |
Why?
|
| Hemorrhoids | 1 | 2007 | 14 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 1441 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 1137 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 183 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3640 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 111 | 0.020 |
Why?
|
| Mitomycin | 1 | 2008 | 213 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3444 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 3844 | 0.020 |
Why?
|
| Anal Canal | 1 | 2007 | 236 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 4048 | 0.020 |
Why?
|
| Heparin | 1 | 2008 | 342 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2006 | 290 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 1189 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4328 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 5315 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 742 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 7757 | 0.010 |
Why?
|
| Neurons | 1 | 2014 | 2439 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 4481 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 5759 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 4223 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 7100 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2006 | 4116 | 0.010 |
Why?
|